Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT05293873

Outcomes of Autologous Bone Marrow-derived Mononuclear Cell Transplantation in the Management of Neurological Sequelae

Outcomes of Autologous Bone Marrow-derived Mononuclear Cell Transplantation in the Management of Neurological Sequelae After Traumatic Brain Injury

Sponsor: Vinmec Research Institute of Stem Cell and Gene Technology

Conditions Sequelae of Injuries of Head

Interventions Rehabilitation therapy autologous bone marrow-derived mononuclear cell transplantation

Updated 5 times since 2022 Last updated: Sep 27, 2024 Started: Apr 1, 2021 Primary completion: Mar 30, 2023 Completion: Jun 30, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Sequelae of Injuries of Head, this trial is completed. The trial is conducted by Vinmec Research Institute of Stem Cell and Gene Technology and has accumulated 5 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Oct 2024 — Present [monthly]

Completed PHASE1/PHASE2
Sep 2024 — Oct 2024 [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Status: Unknown Status → Completed · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Apr 2024 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2

Status: Recruiting → Unknown Status
Apr 2022 — Apr 2024 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Apr 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Vinmec Research Institute of Stem Cell and Gene Technology

Data source: Vinmec Research Institute of Stem Cell and Gene Technology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hanoi, Vietnam